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Ultraviolet radiation plays an important role in the
induction of lesions in many patients with cutaneous
lupus. In the photosensitive subset of lupus, subacute
cutaneous lupus, the effects of ultraviolet radiation
likely act in concert with specific autoantibodies,
particularly anti-Ro-related autoantibodies, to produce
lesions. Potential effects of ultraviolet radiation on the
induction of cutaneous lupus, and the potential interplay
of specific autoantibodies with ultraviolet radiation are
Lupus erythematosus (LE) has long been observed to be aphotosensitive disease (Smith and Cyr, 1988); however,the term ‘‘photosensitivity’’ is poorly defined, even thoughit is a criterion for the classification of systemic LE (Tanet al, 1982). Photosensitivity may mean decreased minimal
erythema dose, a sensation of burning of the skin, exacerbation of
systemic symptoms, or induction of cutaneous lesions upon exposure
of the skin to the sun. A recent study documents the poor correlation
between a personal history of photosensitivity and a decreased minimal
erythema dose (Doria et al, 1996). Another report indicates a frequent
concurrence of transient lesions of polymorphous light eruption in LE
patients, confounding the evaluation of the symptom of photosensitivity
(Hasan et al, 1997). In this review, the term ‘‘photosensitivity’’ will be
used to indicate induction or exacerbation of cutaneous LE lesions as
a result of sun exposure.
Not all LE patients exhibit photosensitivity, and not all cutaneous
manifestations are related to sun exposure. For example, lupus pannicul-
itis and livedo reticularis are not notably affected by the sun. Even
within a category of skin disease, individual patients may respond
differently to sun exposure. Discoid lupus (DLE) lesions may be
initiated or exacerbated by sun exposure in some patients, but may
apparently be unrelated to sun exposure in others (Prystowsky et al,
1975; Lee et al, 1994b). The subset of cutaneous LE that is perhaps
most clearly related to sun exposure is subacute cutaneous LE (SCLE),
and it is on SCLE that this review will focus first. (For categorization
and description of the types of lesions occurring in patients with lupus,
see Sontheimer and Provost, 1996.)
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discussed. The steps involved in the induction of
cutaneous lupus lesions by ultraviolet radiation have
not been fully elucidated. Recent advances in photo-
testing and analysis of the genetics of lupus should
clarify the events leading to photosensitive cutaneous
lupus lesions. Key words: photosensitivity diseases/
lupus erythematosus/ultraviolet radiation/anti-Ro antibodies.
Journal of Investigative Dermatology Symposium Proceedings
4:73–78, 1999
SCLE: THE PROTOTYPE OF PHOTOSENSITIVE
CUTANEOUS LUPUS
SCLE was recognized as a distinctive subset of cutaneous LE by Gilliam
et al in 1979 (Sontheimer et al, 1979). In essence, the same clinical
phenotype was described by Provost et al in their reports of ‘‘ANA-
negative’’ lupus (Provost et al, 1977; Maddison et al, 1981). Evidence
for a role for ultraviolet (UV) exposure in the pathogenesis of SCLE
comes from observations of patients that sun exposure results in lesion
formation, the usual limitation of SCLE lesions to sun-exposed skin
(although the mid-facial skin is characteristically and inexplicably
spared), and the predilection for fair-skinned individuals with skin
phenotype I or II (Sontheimer, 1989; David-Bajar et al, 1992). The
observation that certain photosensitizing drugs, such as thiazide diuretics
and sulfonylureas, can induce SCLE is perhaps also an indication that
sun exposure plays a role in the pathogenesis (Reed et al, 1985).
Finally, as will be discussed later, SCLE lesions can be reproduced by
phototesting, although with more difficulty than expected (Lehmann
et al, 1990).
Two very exciting observations confirmed the uniqueness of SCLE
and provided insight regarding its likely pathogenesis. Sontheimer et al
reported that SCLE is strongly associated with a particularly autoanti-
body specificity, anti-Ro (anti-SSA) (Sontheimer et al, 1982), and
Weston et al reported that neonatal lupus (NLE) is strongly associated
with anti-Ro (Weston et al, 1982). Because the skin disease of NLE is
a photosensitive, non-scarring form of cutaneous LE, it appears to be
the neonatal equivalent of adult SCLE (Lee, 1993). In NLE, the anti-
Ro autoantibodies are produced in the mother and cross the placenta
during pregnancy. The limitation of disease activity in cutaneous NLE
to the first few months of life is a strong indicator of the likelihood
that the maternal anti-Ro antibodies are causing, or at least contributing
to, the disease.
The association of SCLE with anti-Ro explains why patients with
SCLE lesions had previously been characterized as ‘‘ANA negative’’.
Human anti-Ro autoantibodies do not always cross-react with mouse
Ro antigen. In the past years, ANA testing was often performed on
murine tissue, and in that type of assay antibodies to Ro may not be
detected. Current ANA testing is generally performed on human cell
substrates, which are a reliable means of detecting anti-Ro.
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Table I. Ro-associated antigens
Antigen Molecular Function or putative function
weight
60 kDa Ro (Ro60, 60 kDa ? ribosome synthesis, assembly, or
60 kDa SSA) transport; ? salvage pathway for
mutant rRNA precursors
52 kDa Ro (Ro52, 52 kDa ? transcription factor
52 kDa SSA)
La (SSB) 48 kDa control of transcription involving RNA
polymerase III
Calreticulin 46 kDa calcium storage; numerous other
functions and putative functions
Giving credence to the possibility that autoantibodies play a central
role in the pathogenesis of lupus are recent studies of SLE where
extracutaneous disease is reproduced in animals by infusion of anti-
DNA antibodies or by immunization with the Sm autoantigen (Tsao
et al, 1992; James et al, 1995). The anti-Ro autoantibody specificity
has itself been directly implicated in animal models as a cause of the
major extracutaneous manifestation of NLE, congenital heart block
(Alexander et al, 1992; Garcia et al, 1994; Boutjdir et al, 1998; Miranda-
Carus et al, 1998).
Given that autoantibodies are likely to be critically important to
the understanding of SCLE and of photosensitivity in SCLE, the
autoantibodies and autoantigens of SCLE will be described first
before discussing potential links between the autoantibodies and
photosensitivity.
THE AUTOANTIBODIES AND AUTOANTIGENS OF SCLE
Although the autoantibody specificity originally associated with SCLE
is anti-Ro, a multiplicity of anti-Ro-related autoantibody specificities
may be found in SCLE sera. The major specificities include anti-
60 kDa Ro, anti-52 kDa Ro, anti-La, and anti-calreticulin (Table I)
(Lee et al, 1994b; Sontheimer et al, 1995).
The originally described ‘‘Ro’’ antigen is a protein of 60 kDa that
may be bound in vivo to one of four small RNA called ‘‘Y RNA’’ or
‘‘hY RNA’’ (human Y RNA) (Clark et al, 1969; Steitz et al, 1983).
‘‘Ro’’ represents the first two letters of the last name of the index
patient from whom the autoantibodies were characterized. (The ‘‘La’’
and ‘‘Sm’’ antigens were named using the same convention.) An
autoantigen characterized using autoantibodies from patients with
Sjo¨gren’s syndrome and given the name ‘‘SSA’’ was shown to be
identical to ‘‘Ro’’ (Alspaugh and Tan, 1975; Alspaugh and Maddison,
1979). The functions of 60 kDa Ro protein and its associated hY
RNA are not established. It has been proposed that 60 kDa Ro
functions in a salvage pathway for mutant rRNA precursors (O’Brien
and Wolin, 1994). We have closely examined the cellular locations of
60 kDa Ro protein and hY RNA, and have proposed based on their
presence in the nucleolar periphery and in ribosome-rich areas of the
cytoplasm, that they may be involved in ribosome synthesis, assembly,
or transport (Farris et al, 1997). We also noted that, although 60 kDa
Ro protein may be in a complex with hY RNA, separate pools of the
60 kDa Ro protein and the Ro hY RNA exist within the cell.
Two decades after 60 kDa Ro was described, a second specificity
common in anti-Ro-positive sera was discovered and the antigen
identified as a 52 kDa protein (Ben-Chetrit et al, 1988). This protein
was given the name 52 kDa SSA, or 52 kDa Ro. It is reasonable to
expect that there is some relationship between 52 kDa Ro and 60 kDa
Ro, because antibodies to both proteins frequently coexist, but the
nature of that relationship is not entirely clear. There is no sequence
homology between 60 kDa Ro and 52 kDa Ro, yet a cross-reactivity
between native 60 kDa Ro and denatured 52 kDa Ro has been
reported (Itoh et al, 1992). Another group, however, reported a lack
of such cross-reactivity (Yell et al, 1996). A physical association between
52 kDa and 60 kDa Ro/hY RNA has been demonstrated by
immunoprecipitation assays (Slobbe et al, 1991, 1992). Binding of
52 kDa Ro to hY RNA required the presence of 60 kDa Ro, strongly
suggesting that 52 and 60 kDa Ro associate through protein–protein
interaction(s). As is the case for 60 kDa Ro, the function(s) of 52 kDa
Ro are unknown, though sequence similarities and DNA-binding
capability suggest it may act as a transcription factor (Itoh et al, 1991).
The La antigen is a 48 kDa protein that functions in RNA polymerase
III transcription termination (Gottlieb and Steitz, 1989). Though La
binds the 39 termini of numerous RNA polymerase III transcripts
through a common oligouridylate sequence, it is apparently stably
associated with 60 kDa Ro through mutual binding to hY RNA
(Hendrick et al, 1981). Additional sequence elements in a subset of hY
RNA are also bound by La, which might account for the relatively
stable interaction of La with 60 kDa Ro (Pruijn et al, 1991).
Calreticulin is a 46 kDa protein that was initially described as a
calcium-binding protein of the endoplasmic reticulum, but its distribu-
tion within the cell is widespread, and its putative functions are
numerous (Sontheimer et al, 1995). Calreticulin has been reported to
bind both hY RNA and 52 kDa Ro (Cheng et al, 1996). Thus, it
could form a molecular bridge linking the major Ro-associated
molecules.
The physical association of macromolecular complexes of Ro-
associated molecules may explain why antibodies to those molecules
occur so frequently in the same sera. Over the past few years, several
investigators have documented the phenomenon of epitope spreading
(Bockenstedt et al, 1995; James et al, 1995; Topfer et al, 1995). Animals
immunized to a peptide of an autoantigen can, with time, develop
antibodies to other epitopes in the autoantigen, even though the
epitopes are apparently disparate in shape. In some animals, antibodies
may develop not only to epitopes of the original immunizing antigen
but also to proteins with which the original antigen is physically
associated. Epitope spreading has been reported in the cases of
immunization with peptides of 60 kDa Ro, 52 kDa Ro, and La, and
spreading of the anti-Ro response to calreticulin has been observed
(Keech et al, 1996; Kinoshita et al, 1998; McCluskey et al, 1998).
These observations of epitope spreading did not depend upon cross-
reactivities among the proteins involved, but are rather thought to rely
on B cell antigen presentation of multiple epitopes from various
polypeptides within the Ro ribonucleoprotein complex (reviewed in
McCluskey et al, 1998).
Although there are some reasonably well-developed hypotheses
about how it is that multiple autoantibody specificities develop, it is
still not clear how the original autoantibody response arises. One
potential explanation is that an infectious agent containing an epitope
cross-reactive with an epitope of a lupus autoantigen initiates the
response. Once an epitope of the lupus autoantigen is recognized as
foreign, epitope spreading may then occur. The recent population
study of childhood lupus by James et al, showing a far greater prevalence
of immunity to Epstein–Barr virus in the lupus population than in the
control population, provides important evidence for this possibility
(James et al, 1997). She further demonstrated a similarity between an
Epstein–Barr virus epitope and an epitope of the lupus autoantigen, Sm.
Another possibility that is being explored is that the immune response
begins in the skin, as a result of UV-induced damage to keratinocytes.
Casciola-Rosen et al have reported that, during the process of UV-
induced apoptosis, lupus autoantigens such as Ro and La are clustered
within apoptotic cell surface blebs (Casciola-Rosen et al, 1994; Casciola-
Rosen and Rosen, 1997). The blebs could theoretically provide a
means for presenting Ro or La to the immune system in a context
such that the autoantigens are recognized as foreign.
In summary, patients who have antibodies to Ro frequently have
autoantibodies to more than one protein. The multiplicity of autoanti-
bodies found in anti-Ro-positive sera may be explained by physical
association of the autoantigens or by cross-reactivities. Some of the
remaining uncertainties about the functions of the Ro-associated
autoantigens, the clinical significance of antibodies to these antigens,
and the role of specific autoantibodies in pathologic conditions, stem
from the necessity of using patient sera, often containing multiple
autoantibody specificities that are not necessarily trivial to detect.
THE CLINICAL SIGNIFICANCE OF ANTI-RO
Of the Ro-associated autoantibodies mentioned above, antibodies to
60 kDa Ro and La are the specificities about which there is the most
VOL. 4, NO. 1 SEPTEMBER 1999 PHOTOSENSITIVITY AND LUPUS 75
information. This is due in part to the fact that these specificities were
the first to be discovered and in part to the fact that testing for anti-
60 kDa Ro and anti-La is performed in commercial laboratories, often
using relatively straightforward immunodiffusion assays, whereas testing
for anti-52 kDa Ro and anti-calreticulin is generally limited to research
laboratories.
If one examines all patients who have anti-Ro by immunodiffusion
assays, there are numerous clinical findings that may occur. In an
examination by Simmons-O’Brien of 100 patients who had anti-Ro,
the following findings were present in 10% or more of the group
(findings listed in order of frequency, with the most common first):
arthritis, photosensitivity, Raynaud’s phenomenon, nervous system
disease, malar dermatitis, nephritis, pulmonary disease, alopecia, leukop-
enia, pericarditis, cutaneous vasculitis, DLE, decreased complement,
SCLE, and anemia (Simmons-O’Brien et al, 1995). Clearly, only a
minority of patients with antibodies to Ro develop SCLE.
If one examines all patients who have SCLE, however, the majority
have anti-Ro. Admittedly, there is some controversy about the fre-
quency of anti-Ro in SCLE, probably due to differences of opinion
about what constitutes SCLE, as opposed to DLE, lesions. (For
references concerning the distinction between SCLE and DLE, see
David-Bajar et al, 1992; Sontheimer and Provost, 1996.) Notably, the
group that originally defined SCLE identifies anti-Ro in the majority
of patients (Sontheimer, 1989). Our group examined autoantibody
specificities in 17 SCLE patients in detail, examining anti-60 kDa Ro,
anti-52 kDa Ro, and anti-La quantitatively as well as qualitatively (Lee
et al, 1994b). In our study, all SCLE patients examined had high titers
of antibodies to 60 kDa Ro, and most had anti-52 kDa Ro a well. A
minority concurrently had anti-La. These are approximately the same
frequencies we found in neonatal lupus maternal sera (Lee et al, 1994a),
supporting the relationship between NLE and SCLE and also illustrating
that anti-60 kDa Ro is likely the major autoantibody specificity in
these diseases.
The potential importance of anti-Ro in SCLE is underscored by
the finding of anti-Ro in the skin. In immunosuppressed mice with
human skin grafts, injection of anti-Ro antibodies led to preferential
deposition of anti-Ro in the human skin in a particulate epidermal
pattern identical to that seen in adults patients with SCLE and babies
with NLE (Lee et al, 1986b). Our results were confirmed using purified
anti-Ro antibodies and serum from which the anti-Ro specificity had
been removed (Lee et al, 1989). These studies were performed prior
to the discovery of 52 kDa Ro and the development of assays for anti-
52 kDa Ro, so we do not know whether anti-52 kDa Ro contributed
to the cutaneous deposits. Because epidermal IgG deposits were seen
in the skin of an SCLE patient who had no detectable anti-52 kDa
Ro by a sensitive ELISA test, it is likely that anti-60 kDa Ro is
responsible for at least some of the antibody deposits observed, and
also that anti-52 kDa Ro is not required for lesion formation.
The human skin-grafted mouse did not prove to be a good model
for induction of SCLE lesions, and studies of SCLE have been hampered
by the lack of such a model; however, models of cardiac disease in
NLE have been developed, and these strongly support the possibility
that anti-Ro antibodies cause disease (Miranda-Carus et al, 1998).
Given the evidence available, it is reasonable to conclude that anti-Ro
antibodies are necessary but not sufficient for disease to occur, both in
adults with SCLE and in babies with NLE. This conclusion is somewhat
simplistic, in that it is possible that other autoantibodies may on
occasion substitute for anti-Ro. Nevertheless, the general principle
applies that autoantibodies are likely to be necessary, but other factors
must be present as well. This leads to a discussion of the role of UVR
in the induction of lesions.
ULTRAVIOLET RADIATION AND THE INDUCTION OF
SCLE
From a clinician’s perspective, it is obvious that UVR contributes to
the development of SCLE lesions. From the basic scientist’s perspective,
the mechanism of the association of UVR with SCLE is still to be
fully explained (Table II). An early study by LeFeber et al indicated
that UVR of cultured keratinocytes led to increased IgG binding to
Table II. Possible effects of UVR on cutaneous lupus
Modulation of autoantigen location
Apoptosis induction with autoantigens in apoptotic blebs
Induction of nitric oxide synthase expression
Upregulation of adhesion molecules
Expression of pro-inflammatory cytokines
the keratinocyte cell surface (LeFeber et al, 1984). Norris later noted
increased antibody binding as a result of in vivo UV irradiation of
human skin (Norris, 1993). Golan et al independently observed UV-
induced binding of antibodies from anti-Ro-positive sera to a small
percentage of cultured keratinocytes (Golan et al, 1992). One interpreta-
tion of these results is that UVR caused a translocation of Ro antigen
to the cell surface; however, these studies did not employ purified
antibodies, so the contributions of the various Ro-associated antibodies
could not be assessed. In addition, antibody binding to the keratinocyte
was the biologic read-out, and the putative cell surface antigen was
not identified with molecular techniques. Thus, it is not clear whether
the results can be explained by UV translocation of Ro (or other Ro-
associated antigens) to the surface, induction of a cross-reactive antigen
on the surface, or induction of apoptosis and movement of Ro into
apoptotic blebs. Bachmann et al, using a monoclonal anti-La antibody,
suggested that UV translocates La to the surface in the absence of
apoptosis (Bachmann et al, 1990). Sontheimer et al reported that
calreticulin appears on the cell surface as a result of UVR (Kawashima
et al, 1994). However, the concept that intracellular antigens are
translocated to the cell surface following UVR has been somewhat
controversial because there is not an intuitive explanation for why it
is that translocation would occur, at least in cells that are not committed
to an apoptotic death pathway.
We have examined biopsies from patients with SCLE, examining
sun-exposed lesional skin, sun-exposed normal-appearing skin, and
unexposed normal-appearing skin (David-Bajar et al, 1992). All con-
tained immunoglobulin deposits, and the sites sampled were indistin-
guishable with regard to pattern and intensity of immunoglobulin
deposits. Thus, there is not a dramatic in vivo correlation to the
experimental studies mentioned above, and differences in antibody
binding induced by UVR in patients with SCLE would likely be
small. One might postulate that in the baseline situation in vivo in
patients with SCLE, antibody deposits are primarily intracellular. (The
concept that antibodies may bind to the cell surface and then be taken
up into a living cell is itself controversial, but there is experimental
evidence to support this possibility (Koren et al, 1995; Koscec et al,
1997).) Following UVR, a transient increase in antibody binding to
the surface may occur, making the keratinocyte more susceptible to
killing by complement or antibody-dependent cellular cytotoxicity.
This hypothesis could reconcile the previous observations of increased
antibody binding following UVR with the failure to detect increased
antibody deposits in vivo in the sun-exposed skin of SCLE patients;
however, there is not evidence to prove or disprove this hypothesis.
Rather than, or in addition to, acting upon antibody binding,
UVR may exert its effects at points distal to antibody deposition in
keratinocytes. Sontheimer et al have reported that animals pre-treated
with anti-Ro have a lower threshold for UV-induced erythema (Davis
et al, 1989). The mechanism of this effect was not explained, and it
remains to be determined whether and how anti-Ro affects susceptibil-
ity to UV-induced apoptosis, erythema, and inflammation.
Kuhn et al reported that patients with cutaneous LE have aberrant
cytokine-induced nitric oxide synthase (iNOS) regulation following
UVR. Compared with normal controls, LE patients exhibited delayed
onset but considerable prolongation of iNOS expression (Kuhn et al,
1998). How and if this interesting phenomenon is affected by autoanti-
bodies is not yet known.
The effects of UVR on adhesion molecule upregulation and pro-
inflammatory cytokine expression are likely to be relevant in affecting
lymphocyte migration into the skin. For example, UVR induces
a delayed upregulation of ICAM-1 expression in exposed human
keratinocytes, which is thought to be mediated by pro-inflammatory
cytokines (Norris, 1990; Krutmann and Grewe, 1995; Middleton and
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Norris, 1995). Notably, particular patterns of ICAM-1 expression have
been documented in various types of interface dermatitis, with diffuse
epidermal expression occurring in case of SCLE (Bennion et al, 1995).
Lymphocytes that traffic to the skin could conceivably interact with
the ICAM-1 expressing keratinocytes to produce keratinocyte damage.
Alternatively, lymphocytes in the skin could act mainly by releasing
cytokines. A recent report that transgenic mice overexpressing gamma
interferon in the epidermis develop anti-dsDNA and anti-histone
autoantibodies gives credence to the possibility that cytokines released
from lymphocytes could contribute to lupus (Seery et al, 1997). The
relevance of this interesting finding to cutaneous lupus is not yet
known, however. In any case, because a lymphocytic infiltrate is a
hallmark of the pathology of active SCLE lesions, lymphocytes are
probably critical to lesion formation, but the contribution of lympho-
cytes to the pathology of the skin lesions has not been established.
THE LESSONS OF NLE
The reproduction of disease in infants whose mothers have anti-Ro
has proved to be invaluable in understanding the mechanisms whereby
SCLE lesions might occur (Lee, 1993). Some of the more important
clinical observations are as follows: the cutaneous lesions of NLE are
histologically and by immunofluorescence indistinguishable from SCLE
in adults. Like SCLE in adults, the lesions do not typically scar. Almost
without exception, children with cutaneous NLE lesions have maternal
anti-Ro. The cutaneous disease may be present at birth, but more
often appears shortly after birth. In some cases, lesions occur following
sun exposure; however, lesions may appear in relatively sun-protected
areas such as the nappy area. The duration of disease activity ranges
from weeks to months. By 1 y of age at the most, the disease has
resolved. Although virtually all babies with NLE have anti-Ro, only
a small fraction of babies whose mothers have anti-Ro develop NLE.
Even in cases of twins, it is not unusual for one twin to be
affected and the other to be unaffected. There are four major clinical
manifestations of NLE, but it is unusual for a given baby to have more
than one or two. These are cutaneous lupus, congenital heart block
with or without cardiomyopathy, cholestatic liver disease, and throm-
bocytopenia.
Considerable laboratory investigation has been done in NLE and
some of the more significant findings are as follows: Conduction
abnormalities, including heart block, can be reproduced in animal
models by anti-Ro (Alexander et al, 1992; Garcia et al, 1994; Boutjdir
et al, 1998; Miranda-Carus et al, 1998). It is likely, given the information
available, that either anti-52 kDa or anti-60 kDa Ro can produce heart
block. Whereas in our studies anti-60 kDa Ro was found in all NLE
sera tested, anti-52 kDa Ro is also exceedingly common, and both
autoantibodies are candidates for pathogenic autoantibodies in this
disease. The factors responsible for the targeting of one organ versus
another are not known. Antibody deposits can be found in all organs
examined, including organs that are never apparently affected in NLE
(Reichlin et al, 1994). Autoantibody profiles are not demonstrably
different in mothers who have babies with heart block compared with
mothers who have babies with skin disease. In our group, however,
the mothers who had babies with skin disease had lower titers of
circulating anti-60 kDa Ro than did mothers who had babies with
heart block; this is a possible indication of differences in autoantibody–
autoantigen interactions, but the significance of this observation is not
yet known (Lee et al, 1994a).
From these data, one may conclude that autoantibodies are necessary
for disease to occur, but are probably insufficient. The appearance of
disease in one twin but not the other indicates that autoantibody
specificities alone do not determine whether an individual will be
affected or which organs will be involved. In addition, the finding in
autopsy studies and in animal models of antibody deposits in all organs
examined indicates that antibody deposition alone does not determine
disease expression (Reichlin et al, 1994).1 It is unclear what other
1Lee LA, Coulter S, Norris D, Weston WL: An animal model for studying
transplacental passage and tissue deposition of antibody in neonatal lupus. Clin
Res 34:161A, 1996 (abstr.)
factors come into play to produce disease, whether genetic factors,
environmental factors, or a set of random events. UVR is likely an
exacerbating factor in skin disease, but the appearance of lesions at
birth in some babies, and the occasional appearance of lesions in the
nappy area likely means that UVR is unlikely to be required for
cutaneous disease. Interestingly, although a lymphocytic infiltrate is a
hallmark of active cutaneous disease, inflammatory infiltrates are often
not detected in autopsy studies of affected hearts and the significance
of lymphocytes in the pathogenesis of NLE and SCLE is uncertain.
LINKING ANTI-RO WITH DLE
The earlier mentioned studies of SCLE and NLE provide reasonably
convincing evidence for a link between anti-Ro or a closely related
autoantibody specificity and photosensitive cutaneous lupus. Is there a
role for anti-Ro in the more common form of cutaneous lupus,
DLE? Using a standard immunodiffusion (Ouchterlony) technique, the
majority of patients with DLE do not have anti-Ro, and in our studies
of antibody deposition, patients with DLE do not have the epidermal
IgG deposits that can be attributed to anti-Ro but rather have
antibody deposits at the dermal–epidermal junction (Lee et al, 1994b).
Furthermore, a substantial number of DLE patients are not photosensit-
ive. This would seem to indicate that anti-Ro is associated specifically
with photosensitive cutaneous lupus, and in particular, SCLE.
In light of the above, it was surprising that, in a study of autoantibody
specificities in SCLE and DLE, we found a majority of DLE patients
to have anti-Ro (Lee et al, 1994b). Eleven of 15 DLE patients had
IgG anti-Ro by sensitive ELISA techniques. This was largely anti-
60 kDa Ro, although a few had anti-52 kDa Ro. There was not a
clear association between the presence of anti-Ro and the clinical
finding of photosensitivity in the DLE patients. Consistent with
previous studies, a very low frequency of anti-Ro was present in the
DLE patients if standard immunodiffusion was performed; only when
the much more sensitive ELISA techniques were used were the
autoantibodies detected. The likelihood that the ELISA data were
genuine was confirmed by blocking the reactivity of the sera with
purified antigen. In addition, dermatomyositis patient control sera
showed a significantly lower frequency of anti-Ro, so the results were
unlikely to be a non-specific result of having autoimmune cutaneous
disease. One possibility for the high frequency of low-titer anti-Ro in
DLE sera is that the immune response to Ro is intimately linked to
cutaneous lupus, and that in SCLE the response is primarily an
autoantibody response, whereas in DLE the response is primarily cell-
mediated. This possibility fits well with the observation that SCLE
lesions but not DLE lesions occur in newborns, as IgG autoantibodies
cross the placenta with ease, whereas lymphocytes apparently do not.
Another possible interpretation of the autoantibody data is that DLE
patients have an associated autoantibody specificity that is not anti-Ro
but is weakly cross-reactive with Ro.
In summary, there is an intriguing possibility that anti-Ro or closely
related autoantibodies are highly linked to cutaneous lupus, whether
SCLE or DLE, but the true relationship between DLE and anti-Ro
has yet to be elucidated.
PHOTOSENSITIVE CUTANEOUS LE UNASSOCIATED
WITH ANTI-Ro
To conclude that anti-Ro is unrelated to photosensitive cutaneous
lupus is to overlook a great deal of evidence to the contrary; however,
anti-Ro may not be the entire explanation for photosensitive cutaneous
lupus. Particularly in photosensitive DLE, patients may not have
detectable anti-Ro. One possibility, raised above, is that the immune
response to Ro in certain patients may be primarily cell-mediated.
Although that explanation is attractive in certain respects, particularly
with regard to explaining why DLE lesions are rarely, if ever, seen in
infants, it does not explain the reasonably consistent presence of
antibody deposits at the dermal–epidermal junction in DLE lesions.
One would particularly like to know the specificity (-ies) of the
antibodies deposited at the dermal–epidermal junction, but this informa-
tion is not currently available. Because the dermal–epidermal antibody
deposits in DLE are often IgM, perhaps DLE is an IgM-mediated
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Table III. Variants of cutaneous LE and their responses to UV
Clinically Lesions Autoantibody Depth of
photosensitivea reproducible by associations inflammatory
phototestingb infiltrate
ACLEe very frequent minority anti-dsDNA superficial
SCLE very frequent majority anti-Ro and superficial
related abs
DLE occasional minority possibly, low superficial and deep
titer anti-Ro
DDLE often minority, but ? superficial and deep
more than DLE
TLE often majority ? superficial and deep
LEP rare ? ? deep
a‘‘Clinically photosensitive’’ indicates that the patient gives a history of photosensitivity.
The estimates listed represent the anecdotal experience of the one of the authors (LAL).
Not all investigators agree, however, with the high frequency of photosensitivity in ACLE
and SCLE.
bData extracted and summarized from Lehmann et al (1990), Walchner et al (1997), and
Wolska et al (1989).
cACLE, acute cutaneous LE; SCLE, subacute cutaneous LE; DLE, discoid LE; DDLE,
disseminated discoid LE; TLE, tumid LE; LEP, LE panniculitis.
disease that does not occur in infants because IgM does not cross the
placenta. In any case, searches by our laboratory for specific IgM
autoantibodies in DLE sera have not been fruitful. Finally, photosensitive
cutaneous lupus in patients who do not have anti-Ro could be related
to other IgG antibody specificities, such as anti-U1RNP, which has
been found in a handful of cutaneous NLE patients (Provost et al, 1987).
PHOTOTESTING
A major impediment to the understanding of the pathogenesis of
photosensitive cutaneous lupus is the lack of an optimal animal model
of disease. For example, although the cardiac conduction defect of
NLE has been reproduced, the cutaneous SCLE lesions have not.
Reproduction of disease in humans would be extremely useful, but
has been difficult to achieve. Although reproduction of lesions in
patients with known cutaneous lupus does not allow for the study of
events that take place long before the first cutaneous lesion becomes
evident, it would at least illuminate the events that take place proximate
to lesion formation. Recently, protocols for phototesting have been
optimized by taking into account multiple parameters such as light
source, area of skin irradiated, site of irradiation, dose of UV, frequency
of irradiation, and time to induction of lesions. All of these factor into
success or lack of success of phototesting (Walchner et al, 1997).
Phototesting has confirmed that some patients with cutaneous lupus
have lesions that can be initiated by UV exposure, and has substantiated
differences in clinical subsets of cutaneous lupus with regard to response
to UV (Table III). In general, lesions of SLE (presumably, acute
cutaneous lupus) can be reproduced in about one-fourth of patients
tested, lesions of SCLE in about two-thirds, and lesions of DLE in
about one-third (Wolska et al, 1989; Lehmann et al, 1990; Walchner
et al, 1997). Within the DLE group, patients who have disseminated
lesions are much more likely to have lesions reproduced by phototesting.
Wolska et al were able to reproduce lesions in nine of 21 patients with
disseminated DLE but only in nine of 90 patients with limited DLE
(Wolska et al, 1989). A somewhat surprising finding is the high
frequency of photo-reproduction of lesions in patients who have tumid
lupus. Tumid lupus is an unusual variant characterized by indurated
erythematous plaques that appear morphologically similar to edematous
plaques of polymorphous light eruption. About four-fifths of patients
with tumid lupus had lesions reproduced in phototesting (Lehmann
et al, 1990; Walchner et al, 1997). Further studies using photo-
reproduction of lesions should result in better understanding of the
events that occur during lesion formation.
THE FUTURE
As should be evident from this review, it is clear that UV radiation
plays a major role in the induction of lesions in some patients
with cutaneous lupus, particularly patients with SCLE; however, the
mechanisms whereby UV radiation results in lesion formation have
not been fully elucidated. In the future, studies of pathomechanisms
of lesion formation using phototesting of humans with lupus should
help identify the steps involved in the induction of lesions. In addition,
studies of the complex genetics of lupus have the potential to identify
factors involved in disease formation, including factors involved long
before disease becomes evident. Finally, determination of the functions
of the lupus autoantigens, such as Ro, along with the effects of
autoantibody binding on autoantigen function or other cellular func-
tions may help explain the relationship of specific autoantibodies to
cutaneous disease.
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